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rx1 and pax6 are necessary for the establishment of the vertebrate eye field and for the maintenance of the retinal stem cells that give rise to
multiple retinal cell types. They also are differentially expressed in cellular layers in the retina when cell fates are being specified, and their
expression levels differentially affect the production of amacrine cell subtypes. To determine whether rx1 and pax6 expression after the eye field
is established simply maintains stem cell-like qualities or affects cell type differentiation, we used hormone-inducible constructs to increase or
decrease levels/activity of each protein at two different neural plate stages. Our results indicate that rx1 regulates the size of the retinal stem cell
pool because it broadly affected all cell types, whereas pax6 regulates more restricted retinal progenitor cells because it selectively affected
different cell types in a time-dependent manner. Analysis of rx1 and pax6 effects on proliferation, and expression of stem cell or differentiation
markers demonstrates that rx1 maintains cells in a stem cell state by promoting proliferation and delaying expression of neural identity and
differentiation markers. Although pax6 also promotes proliferation, it differentially regulates neural identity and differentiation genes. Thus, these
two genes work in parallel to regulate different, but overlapping aspects of retinal cell fate determination.
© 2007 Published by Elsevier Inc.Keywords: six3; sox2; notch1; ngn1; neuroD; p27; Xath5; XenopusIntroduction
The development of the retina involves the interplay of many
factors at several developmental time points. Embryonic
precursors are biased toward a retinal fate by interactions and
signaling factors that pattern the early embryo (reviewed in
Zaghloul et al., 2005). At neural plate stages signaling from the
underlying mesoderm establishes the eye field, whose cells are
specified to give rise to the retina by several genes, such as rx1,
pax6 and six3 (reviewed in Wawersik and Maas, 2000;
Marquardt and Gruss, 2002; Zuber et al., 2003; Zaghloul et
al., 2005). These genes continue to be expressed in retinal stem
(RSC) and progenitor (RPC) cells in the optic vesicle, optic cup
and ciliary marginal zone (CMZ) of the mature retina.⁎ Corresponding author. Fax: +1 202 994 8885.
E-mail address: anasam@gwumc.edu (S.A. Moody).
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doi:10.1016/j.ydbio.2007.03.017Numerous homeodomain and bHLH transcription factors are
subsequently involved in specifying the different retinal cells
types (reviewed in Hatakeyama and Kageyama, 2004; Zaghloul
et al., 2005; Wang and Harris, 2005). However, those genes that
initiate the eye field also are differentially expressed in retinal
layers as the retina matures (Hirsch and Harris, 1997; Harris and
Perron, 1998; Perron et al., 1998; Perron and Harris, 1999),
suggesting that they also may play a role in cell type
specification. It has been difficult to study their potential
additional functions at later developmental times, however,
because they are required for the initial establishment of the eye
field (Hill et al., 1991; Grindley et al., 1995; Mathers et al.,
1997; Hirsch and Harris, 1997; Gehring and Ikeo, 1999;
Fitzpatrick and van Heyningen, 2005).
Although several early lineage studies suggested that retinal
cell type specification was a late event in retinogenesis, labeling
of individual eye field cells demonstrated that the eye field
contains at least two different types of RSC/RPC that give rise
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reviewed in Zaghloul et al., 2005). The eye field also is
characterized by molecular heterogeneity; the three retinal stem
cell genes (rx1, pax6, six3) are expressed in overlapping, but
not identical, patterns in the eye field, suggesting that RSCs and
subsequent RPCs express different combinations of these genes.
For example, differential expression of homeodomain transcrip-
tion factors in conjunction with bHLH transcription factors in
retinal progenitors alters their contribution to mature retinal cell
types (Wang and Harris, 2005). Furthermore, since different
neurotransmitter subtypes of amacrine cells are derived from
different sets of embryonic precursors (Huang and Moody,
1995, 1997), and inner nuclear layer (INL) cells (which include
amacrine cells) arise from restricted progenitors in the eye field
(Moody et al., 2000), it is possible that differential expression of
the RSC genes may initiate the process of amacrine cell
specification shortly after they establish the eye field. To test
this possibility, we made hormone-inducible constructs of rx1
and pax6 to alter the expression levels of these genes after the
eye field is formed. We found that increased levels of Rx1 in the
early eye field promotes neuropeptide Y (NPY) amacrine cells
and represses GABA and dopamine (DA) amacrine cells, and in
the late eye field significantly represses DA and NPY
phenotypes (Zaghloul and Moody, 2007). Increased levels of
Pax6 in the early eye field represses NPYand DA amacrine cells
but does not affect the GABA phenotype, and in the late eye
field significantly represses only the DA phenotype. These
results indicate that levels of Rx1 and Pax6 differentially
modify the ability of cells in the eye field to produce the
different neurotransmitter subtypes of amacrine cells.
To determine if the effects reported above are specific to
amacrine subtypes, herein we extend these analyses to
representative cells in all of the retinal layers for two reasons.
First, since rx1 and pax6 are considered important for the
maintenance of RSCs and the ability to give rise to multiple
cells types in the retina (Marquardt et al., 2001; Casarosa et al.,
2003), their increased levels may in fact repress the differentia-
tion of all cell types. Second, based on their later expression
patterns in the layered retina, if they promote specification of
certain cell types, one would expect: 1) rx1 to promote cell
types located in the outer nuclear layer (ONL) and outer portion
of the INL (OINL) and/or repress those in the inner portion of
the INL (IINL) and ganglion cell layer (GCL); and 2) pax6 to
promote cell types located in the IINL and GCL and/or repress
those in the ONL and OINL. Our results suggest that rx1
regulates the size of the RSC pool because it broadly affected all
retinal cell types, whereas pax6 regulates the formation of
certain types of RPCs because it selectively affected different
cell types in a time-dependent manner. Analysis of the effects of
altering the levels/activity of Rx1 and Pax6 on proliferation, and
expression of stem cell or differentiation markers demonstrates
that rx1 maintains cells in a stem cell state by promoting
proliferation and delaying expression of neural identity and
differentiation markers. Although pax6 also promotes prolifera-
tion, it does not maintain stem cell markers but differentially
regulates neural identity and differentiation genes. We propose
that these two genes work in parallel to regulate different, butoverlapping aspects of retinal cell fate determination during the
eye field stages.
Materials and methods
Generation and collection of embryos
Fertilized Xenopus laevis embryos were obtained from adult frogs induced
to mate after injection of human chorionic gonadotropin. After chemical
removal of the jelly coat, embryos were selected as previously described
(Moody, 2000) to target the major blastomere precursor of the retina (blastomere
D1.1.1; Huang and Moody, 1993).
Targeted microinjection of synthetic mRNAs
To increase protein levels at desired developmental times, hormone-
inducible vectors of rx1 (Mathers et al., 1997) and pax6 (Hirsch and Harris,
1997) were constructed by fusing their coding regions to the ligand-binding
domain of the human glucocorticoid receptor (GR) by PCR (described in Kolm
and Sive, 1995; Zaghloul and Moody, 2007). For loss-of-function experiments,
hormone-inducible constructs containing the coding regions of previously
characterized dominant-negative rx1 (rx1EnR; Andreazzoli et al., 1999) and
dominant-negative pax6 (dnpax6; Chow et al., 1999) were similarly made
(Zaghloul and Moody, 2007). Capped, polyadenylated mRNAs were synthe-
sized in vitro (Ambion, Inc.) and mixed at concentrations of known phenotypes
(rx1, 50 pg; pax6, 50 pg; rx1EnR, 400 pg; dnpax6, 60 pg) with gfp (150 pg) or
βgal (100 pg) mRNA as lineage tracers. Each experimental mRNAmixture was
microinjected (1 nl) into blastomere D1.1.1 on one side of the embryo.
Exogenous gene expression was targeted to this blastomere, which produces
50–60% of retinal cells (Huang and Moody, 1993), to avoid a global effect on
the eye field that might perturb later retinogenesis.
After mRNA injection, the cells synthesize the fusion proteins, but the GR
domain forms a complex with endogenous heat shock proteins that prevents the
transcription factor from entering the nucleus (Mattioni et al., 1994; Kolm and
Sive, 1995). To uncouple this complex and allow nuclear translocation, injected
embryos were incubated in synthetic hormone (10 μM dexamethasone)
according to published protocols (Kolm and Sive, 1995). To ensure that the
GR constructs function as expected, injected embryos were treated with
hormone immediately after mRNA injection; for each construct these embryos
phenocopied those injected with the non-GR versions (Hirsch and Harris, 1997;
Mathers et al., 1997; Andreazzoli et al., 1999; Chow et al., 1999), as reported in
Zaghloul andMoody (2007). For the experiments reported herein, embryos were
continuously exposed to hormone starting at two different time points in eye
field development (stage 12, early neural plate; stage 16, neural fold;
Nieuwkoop and Faber, 1994) to discern whether there is a time window for
the observed effects. Experiments in tissue culture and in whole embryos with
similar GR-fusion constructs indicate that robust protein activation occurs
rapidly (within 90 min) after hormone treatment, and is maintained for several
days (Hollenberg et al., 1993; Mattioni et al., 1994; Kolm and Sive, 1995; De
Graaf et al., 1998). Therefore, we assume that the GR-fusion proteins are
available to affect downstream targets throughout the culture period of our
experiments. To demonstrate that the GR-constructs have no effects in the
absence of hormone, we previously injected embryos with the GR-constructs
and raised them in the absence of hormone; no morphological abnormalities
were observed and dopamine amacrine cell numbers were unchanged from
controls (Zaghloul and Moody, 2007) in accord with published accounts
(Hollenberg et al., 1993; Mattioni et al., 1994; Kolm and Sive, 1995; De Graaf et
al., 1998). To demonstrate that hormone treatment alone does not affect
differentiated retinal cell fates, we previously injected control embryos with only
gfp mRNA and treated them with dexamethasone at eye field stages; cell counts
of dopamine amacrine cells from these embryos were identical to those from gfp
mRNA-injected embryos not exposed to hormone (Zaghloul and Moody, 2007).
Furthermore, dexamethasone treatment of control embryos did not alter the
mean number of apoptotic cells in the optic vesicle (1.34±0.22), as assessed by
the TUNEL assay (see below) compared to untreated embryos (1.85±0.27;
p>0.05). Dexamethasone treatment of control embryos also did not change
the types of tissues populated by the D1.1.1 lineage (Fig. 3).
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TUNEL assay
Embryos were raised in the continuous presence of hormone to stage 38 for
analysis of horizontal cells or stage 44/45 for analysis of all other cell types,
fixed in 4% paraformaldehyde solution (MEMFA; Sive et al., 2000) and scanned
for GFP expression to analyze only embryos in which exogenous gene
expression was successful. Embryos were cryoprotected overnight at 4 °C in
30% sucrose/0.1M phosphate buffer solution, embedded in Tissue-Tek OCT
medium (Miles, Inc.), and cut serially (14 μm) with a cryostat. Immunostaining
was carried out as previously described (Huang and Moody, 1995) using rabbit
anti-Calbindin D-28K (Chemicon) for cone photoreceptors (1:200) and rabbit
anti-GABA (Immunostar, Inc.) for horizontal cells (1:500). AlexaFluor-
conjugated Texas Red goat anti-rabbit IgG secondary antibodies (Molecular
Probes) were applied at a concentration of 1:200. Sections were analyzed using
an epifluorescence microscope equipped with a dual pass GFP/Texas Red barrier
filter set. The total number of immunolabeled cells was counted in every section
through the retina, and the proportion of those that were also labeled with GFP
(i.e., derived from the genetically altered lineage) was calculated. To identify
ganglion cells, sections were incubated in 4, 6-diamidino-2-phenylindole
(DAPI) (1:5000) to label cell nuclei, and all nuclei within the GCL were
counted. Percent contributions of the D1.1.1 lineage to a particular cell type
from each experimental condition were compared to those from gfp mRNA-
injected control embryos that were similarly treated with dexamethasone (n=10
embryos per data set) by the Student's unpaired t-test (α<0.05); each treatment
data set passed the equal variance test.
Proliferating cells were identified by immunostaining with an antibody that
recognizes the phosphorylated state of histone H3 (PH3). This protein is
expressed only in cells which are in the prophase of mitosis (Hendzel et al.,
1997). To determine the mitotic index of clones, the number of cells in the clone
(marked by cytoplasmic β-Gal) expressing PH3 as well as the total number of
cells (labeled by DAPI nuclear staining) in the clone were counted at optic
vesicle stages (stage 20/21). The mean mitotic indices for dexamethasone-
treated control (n=12) and experimental (n=10 per group) groups were
compared by the Student's unpaired t-test, as above.
To determine whether alterations in gene expression caused apoptotic cell
death, β-gal (control) and experimental mRNA-injected embryos were treated
with dexamethasone at stage 12 and raised to stages 21/22 and 25/26. After
fixation in MEMFA, the vitelline membranes were removed and the embryos
were stained for the presence of β-Gal to identify the injected side of the
embryo. The embryos were post-fixed and further processed for the TUNEL
assay according to the manufacturer's protocol (In Situ Cell Death Detection
Kit, AP; Roche). After the chromogenic reaction using BM Purple (Roche),
embryos were fixed, bleached to remove skin pigment and cleared with BB/BS.
The number of apoptotic cells within the retina was counted and compared by
the Student's unpaired t-test, as above.In situ hybridization
Embryos were fixed in MEMFA to visualize gene expression at optic vesicle
(stages 20–22), optic cup when the first post-mitotic cells appear (stages 25–28),
embryonic retina when the first born cells begin to differentiate (stages 32–34),
and early larval retina when all cell types have begun to differentiate (stage 38). A
histochemical reaction was done to visualize the location of the β-Gal labeled
cells and in situ hybridization carried out according to standard protocols using
digoxygenin-labeled antisense RNA probes (Sive et al., 2000). In all experiments
control embryos were treated with dexamethasone. rx1, pax6 and six3 probes
were used as markers of retinal stem cells. notch1 and sox2 probes were used as
markers of neural stem cells. ngn1, p27, neuroD and Xath5were used as markers
of early differentiation. Effects of altering gene levels starting at stage 12 versus
stage 16 were compared by Chi-square analyses to detect potential temporal
differences in gene effects. To visualize expression domains in the late retina
(stage 38), whole mount preparations were sectioned with a vibratome. To
determine whether increased levels of Rx1 or Pax6 caused D1.1.1 progeny to
change from a retinal fate, embryos also were analyzed for expression of chordin
(dorsal mesoderm), Nkx2.4 (ventral forebrain) and pax2 (optic stalk) and a
lineage map of the D1.1.1 clone was constructed (Moody, 1987).Calculation of retinal volumes and optic cup size
To determine effects on the volume of the differentiated retina, both control
and experimental mRNA injected embryos were treated with hormone at stage
12 and raised to stage 44/45. Embryos were fixed in MEMFA, cryoprotected
overnight in 30% sucrose solution and sectioned at 14 μm with a cryostat. The
area of each section through an entire retina was measured from a video image
captured directly from the microscope using a Hamamatsu Argus-10 image
processor. The volume of each retina was calculated by summing the section
area and multiplying by section thickness. To determine whether the effects were
manifested at the initiation of retinal development, the width of the optic cups,
stained by in situ hybridization with rx1 probe, in stage 25 experimental and
control mRNA-injected, hormone-treated embryos were measured with a
stereomicroscope equipped with an eyepiece micrometer. Widths were
expressed as the number of divisions (arbitrary units) of the eyepiece micrometer
at 64X magnification. For both sets of measurements, mean values for
dexamethasone-treated control (n=12) and experimental (n=10 per group)
values were compared by the Student's unpaired t-test, as above.Results
Changes in Rx1 levels/activity at eye field stages affect several
retinal cell types
In the layered Xenopus retina, rx1 is expressed both in the
RSC of the CMZ and in cells in the ONL and OINL. Previous
work demonstrated that increasing rx1 levels after eye field
formation reduces three amacrine cell subtypes (Zaghloul and
Moody, 2007), promotes photoreceptor cell fate (reviewed in
Bailey et al., 2004) and represses ganglion cell fate (Sakagami et
al., 2003). This might occur because increasing Rx1 levels at this
stage: (1) preferentially promotes ONL andOINL cell types and/
or represses IINL (e.g., amacrine) and GCL cell types; or (2)
maintains a multipotent cell state that retards the differentiation
of all cell types. To distinguish between these possibilities,
markers for cells in the other retinal layers were analyzed. At
stage 44/45, cone photoreceptors (ONL) are specifically labeled
with calbindin antibodies and ganglion cell nuclei (GCL) can be
identified by DAPI staining; at stage 38, GABA antibodies label
horizontal cells (OINL) (Figs. 1A–C).
To avoid altering Rx1 levels during the specification of the
initial RSCs that constitute the eye field, the Rx1-GR protein was
activated by hormone at either early (stage 12) or late (stage 16)
neural plate stages. If rx1 acts to promote ONL and/or OINL cell
types at these stages, then cone and horizontal cell numbers
should increase after increasing Rx1 levels and decrease after
Rx1 loss-of-function. If rx1 acts to suppress IINL and GCL cell
types at these stages, then amacrine and ganglion cell number
should decrease after increasing Rx1 levels and increase after
rx1 loss-of-function. Instead, increasing rx1 levels within the
D1.1.1 lineage at either stage significantly reduced all monitored
cell types (Figs. 1D–F); GABA amacrine cells, which account
for about 95% of the amacrine cells at this developmental stage
in Xenopus (Huang and Moody, 1998), also were decreased
(Zaghloul and Moody, 2007). Because all cell types are reduced
by increased Rx1 levels, this gene appears to promote an
undifferentiated RSC state at these stages rather than specific cell
type formation. This reduction is not likely to be due to increased
cell death because the mean number of apoptotic cells per retina
Fig. 1. Altered levels of rx1 expression affect blastomere D1.1.1 contributions to retinal cell types. (A–C) Representative cell types from each cell layer were labeled
by immunofluorescence for: (A) calbindin-positive cone photoreceptors (red) in the ONL [bar=40 μm]; (B) GABA-positive (red) horizontal cells in the OINL (note
that GABA also stains amacrine cells in the IINL) [bar=30 μm]; (C) DAPI-positive nuclei (blue) of ganglion cells in the GCL [bar=30 μm]. For panels A–C,
arrowheads note GFP-labeled (green) descendants of blastomere D1.1.1. L, lens. (D–F) Activation of Rx1-GR protein at early (St. 12) and late (St. 16) neural plate
stages decreased cell numbers significantly (*p<0.05 cf. GFP-injected hormone treated controls) for all three cell types. (G–I) Activation of Rx1EnR-GR protein at
St. 12 significantly decreased ganglion cells. Activation at St. 16 significantly increased cone and ganglion cell numbers, but horizontal cells were unchanged.
(*p<0.05 cf. GFP-injected hormone treated controls; **p<0.05 cf. stage 12). Bars indicate SEM.
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different from dexamethasone treated controls (p>0.05).
Decreasing rx1 target gene activation with the rx1EnR-GR
construct beginning at stage 12 reduced the number of ganglion
cells, whereas cone and horizontal cell numbers did not change
significantly (Figs. 1G–I). Decreasing rx1 target gene activation
beginning at stage 16 significantly increased cone and ganglion
cell numbers but did not affect horizontal cells (Figs. 1G–I).
GABA amacrine cell numbers also were increased at both
stages of hormone treatment (Zaghloul and Moody, 2007).
These loss-of-function data indicate that: (1) early neural plate
expression of rx1 is required for ganglion cells, but the other
cell types can differentiate in its absence; and (2) late neural
plate expression of rx1 is not required for any of the cells types;
in fact rx1 probably inhibits the differentiation of cone, GABA
amacrine and ganglion cells since their cell numbers increase in
its absence. Since the mean number of apoptotic cells per retina
at stage 21 (0.80±0.16) or stage 26 (1.65±0.30) did not differfrom dexamethasone-treated controls (p>0.05), these observa-
tions are not the result of selective cell death.
Changes in Pax6 levels/activity at eye field stages selectively
affect retinal cell types
In the layered retina, pax6 is expressed both in the RSC of
the CMZ and in cells in the IINL and GCL. Previous work
demonstrated that increasing levels of pax6 after eye field
formation reduces only DA and NPY amacrine cells, two rare
subtypes, but has no detectable effect on the major amacrine
subtype that expresses GABA (Zaghloul and Moody, 2007),
consistent with a conditional loss-of function mouse mutant
showing that pax6 is required for all cell types except amacrine
cells (Marquardt et al., 2001). To test whether increasing Pax6
levels at this stage preferentially promotes IINL and GCL cell
types and/or represses ONL and OINL cell types, Pax6-GR was
activated by hormone at two different neural plate stages.
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horizontal cells, increased ganglion cells and did not change
cone cell numbers, whereas increasing Pax6 levels at stage 16
only repressed cone cells (Figs. 2A–C). GABA amacrine cell
numbers were unaffected at either stage (Zaghloul and Moody,
2007). The observed reduction in cell numbers is not likely to be
due to increased cell death because the mean number of
apoptotic cells per retina at either stage 21 (0.60±0.15) or stage
26 (1.75±0.48) was not different from dexamethasone treated
controls (p>0.05).
Decreasing Pax6 activity by activating the dnPax6-GR
protein at stage 12 significantly increased horizontal cell
numbers but had no detectable effect on cone or ganglion cells
(Figs. 2D–F). In contrast, decreasing Pax6 activity at stage 16
significantly increased cone and ganglion cell numbers, whereas
horizontal cell numbers were not affected (Figs. 2D–F). GABA
amacrine cell numbers were increased after pax6 loss-of-
function at both stages (Zaghloul and Moody, 2007). These
observations are not likely to be due to increased cell death
because the mean number of apoptotic cells per retina at either
stage 21 (0.80±0.19) or stage 26 (1.35±0.17) was not different
from dexamethasone treated controls (p>0.05). Together these
data indicate that after the eye field forms, increased pax6 levels
at stage 12 preferentially promote ganglion cells and repress
horizontal cells, and at stage 16 preferentially repress cone cells.
To ensure that these changes in retinal cell types are not the
result of retinal lineages being diverted to other cell fates, we
monitored the D1.1.1 lineage in βGal, rx1-GR and pax6-GR
mRNA injected embryos. In all cases the D1.1.1 cells populated
their normal tissues (cf. Moody, 1987), including diencephalon,
retina, epidermis and branchial arch mesoderm, both in the
presence and absence of hormone (Fig. 3). Increasing Rx1
(n=20) or Pax6 (n=20) also did not alter the expression ofFig. 2. Altered levels of pax6 expression differentially affect blastomere D1.1.1 contr
(St. 12) significantly decreased horizontal cells and increased ganglion cells (*p<0.0
photoreceptors were significantly decreased, whereas cone and ganglion cell numbers
GR protein at St. 12 significantly increased horizontal cells. Activation at St. 16 signi
to control level. (*p<0.05 cf. GFP-injected hormone-treated controls; **p<0.05 cfchordin, a dorsal mesoderm gene, nor was the distribution of
D1.1.1 progeny within this tissue different from controls (data
not shown). Further, the expression patterns of a ventral
forebrain gene (Nkx2.4) and an optic stalk gene (pax2) were not
altered by mRNA injection or hormone treatment and there was
no evidence that β-Gal expressing cells were diverted out of the
retina into the alternate ventral diencephalic domains of these
genes (Fig. 3). These results indicate that the reduction in the
D1.1.1 contribution to retinal cell types following increased
levels of Rx1 or Pax6 at eye field stages is not due to the cells
changing fate to populate other tissues or CNS domains.
Rx1 promotes a proliferative, undifferentiated RSC state
Previous studies showed that rx1 overexpression resulted in
ectopic eye tissue, whereas loss of rx1 by gene knockout in
mice or by expression at blastomere stages of a dominant-
negative construct in Xenopus resulted in the formation of a
small eye (Mathers et al., 1997; Andreazzoli et al., 1999). These
results and our observation that increased Rx1 levels decreases
the numbers of differentiated cells in all layers (Fig. 1) are
consistent with the suggestion that rx1 maintains a stem-like,
multipotent state (Casarosa et al., 2003). If true, then increased
Rx1 levels should increase cell proliferation, maintain stem cell
marker genes longer through development and/or expand their
expression domains, and delay or repress differentiation marker
genes. If instead rx1 affects retinal cell type specification, then
increased Rx1 levels should have differential effects on neural
identity and differentiation genes that promote certain cell types
(reviewed in Hatakeyama and Kageyama, 2004).
Increasing Rx1 levels at stage 12 resulted in a significant
increase in the proportion of mitotic cells within the clone at
optic vesicle stages (stage 20/21) compared to controls (Figs.ibutions to cell types. (A–C) Activation of Pax6-GR protein at early neural plate
5 cf. GFP-injected hormone-treated controls). At late neural plate (St. 16), cone
returned to control level. (**p<0.05 cf. stage 12). (D–F) Activation of dnPax6-
ficantly increased cones and ganglion cells, but horizontal cell numbers returned
. stage 12). Bars indicate SEM.
Fig. 3. Activation of Rx1-GR or Pax6-GR protein at stage 12 does not cause cells to contribute to alternate cell fates. Cells descended from the mRNA-injected D1.1.1
blastomere (red) contribute to head tissues in a pattern identical to normal fate maps (cf. Moody, 1987), including diencephalon (d), lateral epidermis (e), retina
(r; outlined), and branchial arch mesoderm (ba). These patterns are consistent regardless of which mRNAwas injected (βGal, rx1, pax6), and whether hormone (dex)
was added to the culture medium. The expression domains of Nkx2.4 in the ventral diencephalon and pax2 in the optic stalk did not change after any of the treatments.
Bar=100 μm.
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resulted in a significant decrease (Figs. 4A, F). These data
correlate with significant increases in the size of the early optic
cup (stage 25) and mature retina (stage 44) after increasing Rx1
and significant decreases in rx1 loss-of-function embryos (Figs.
4B, C). After both Rx1 increase and rx1 loss-of-function, the
differences between control and injected retinas were less
dramatic in the mature retina, suggesting that the effect is
attenuated over time. These results demonstrate that rx1
expression in the eye field is necessary and sufficient to expand
the proliferative pool of cells from early optic vesicle stages
throughout embryonic retinogenesis.
If rx1 affects retinal cell fates simply by expanding and/or
maintaining the RSC pool as predicted from the proliferation
data, then increased Rx1 levels should expand the expression of
retinal stem cell genes and repress the expression of
differentiation genes. To test this, several marker genes were
analyzed at different stages of retinal development. pax6 and
six3 were used as markers of RSCs. Both are expressed in the
early eye field and continue to be expressed throughout the
optic vesicle, optic cup, and all zones of the CMZ. In addition,
as layers develop pax6 and six3 are expressed in the GCL and
INL (Perron et al., 1998; Perron and Harris, 1999; Figs. 5A, D–
G). notch1 and sox2 were used as markers of neural stem cells.
notch1 is expressed in the developing nervous system,
including the optic vesicle, optic cup, zone 2 and 3 of the
CMZ, GCL and INL, and inhibits the differentiation of cells
(Coffman et al., 1993; Perron and Harris, 1999; Figs. 5A, H, I).
sox2, a member of the Group B1 Sox genes, functions to
maintain undifferentiated neural precursors (Sasai, 2001;
Bylund et al., 2003) and is expressed in the optic vesicle,
optic cup, CMZ, GCL and INL (Figs. 5A, J, K). Both notch1
and sox2 are thought to maintain the neural identity of nervoussystem stem cells (Hitoshi et al., 2002; Graham et al., 2003).
ngn1, p27, neuroD and Xath5 were used as markers of
differentiation. ngn1 is a bHLH factor that promotes neuronal
differentiation upstream of other neurogenesis genes (Ma et al.,
1996) and is expressed in the optic cup and all layers of the
central retina; it is absent from the CMZ at stage 38 (Figs. 5A, L,
M). p27 is a cyclin-dependent kinase inhibitor that inhibits cell
cycle genes, and promotes cell cycle exit and subsequent
differentiation by interacting with and stabilizing bHLH
proteins (Su et al., 1995; Ohnuma et al., 1999; Vernon et al.,
2003). It is expressed in the optic cup, zones 2 and 3 of the
CMZ, GCL and INL (Figs. 5A, N, O). neuroD, a bHLH gene, is
expressed later than ngn1 in the optic cup, zone 3 of the CMZ,
GCL and INL, and promotes the formation of differentiated
neurons (Lee et al., 1995; Perron and Harris, 1999; Figs. 5A, P,
Q). Xath5 is a proneural bHLH factor expressed exclusively in
the optic cup, zone 3 of the CMZ and GCL of the developing
retina and interacts with other factors in the retina to promote
the differentiation of retinal neurons (Kanekar et al., 1997;
Perron and Harris, 1999; Figs. 5A, R, S). Our observations,
made at stage 38, indicate that rx1, pax6 and six3 are expressed
by RSCs (zones 1, 2, 3) and RPCs (zones 2, 3) in the CMZ and
in different subsets of differentiating cells in the forming layers.
notch1 is expressed in RPCs (zones 2, 3) and some
differentiating cells. sox2 is expressed by RSCs, RPCs and
some differentiating cells. ngn1 is expressed by differentiating
cells whereas p27, neuroD and Xath5 are expressed in subsets
of RPCs (zone 3) and different subsets of differentiating cells.
The expression patterns observed here are consistent with those
previously published for stage 44 (Perron et al., 1998; Perron
and Harris, 1999; Ohnuma et al., 1999). The expression patterns
for all of these genes in dexamethasone treated control embryos
were indistinguishable from untreated controls (not shown).
Fig. 4. Changing Rx1 and Pax6 levels/activity at stage 12 alters proliferation and
the size of the retina. (A) rx1-GR (rx1) and pax6-GR (pax6) expressing clones
contained a significantly larger proportion of mitotic cells than control (β-Gal)
clones, whereas loss-of-function of rx1 (rx1EnR) or pax6 (dnpax6) resulted in a
significantly decreased mitotic index. The mitotic indices of clones at stage 20
(optic vesicle) that descended from blastomere D1.1.1 were calculated by
counting the number of cells in the clone (D–F, blue cytoplasm) that expressed
phosphohistone-H3 (D–F, brown nuclei), a marker specific to mitotic prophase.
Arrowheads note representative double-labeled cells. Bar=10 μm. (B) The
width of the optic cup at stage 25 was significantly larger when Rx1 or Pax6
levels were increased and significantly smaller when rx1EnR or dnpax6
mRNAs were expressed. (C) Retinal volume at stage 44/45 was significantly
larger when Rx1 or Pax6 levels were increased and significantly smaller when
rx1EnR or dnpax6 mRNAs were expressed. (*p<0.05 cf. β-Gal or GFP dex-
treated controls). Bars indicate SEM.
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CMZ provides evidence that the cells located in those regions
are the earliest RSCs whereas expression of differentiation
markers in zones 2 and 3 of the CMZ suggest that the cells
located there are more mature RPCs that are in transition
between a stem cell state and the differentiating cells located in
the layers of the central retina.
Markers were analyzed at early optic vesicle (stages 20–23),
optic cup (stages 25–28) when the first post-mitotic cells appear,
embryonic retina (stage 32; early differentiation) and early larval
retina (stage 38) when all cell types have begun to differentiate
and all cell layers begin to form. Rx1-GR protein was activated
at early (stage 12) and late (stage 16) neural plate stages to
identify any potential temporal differences in its effects. Twoaspects of expression of each marker were independently
determined. First, embryos were scored for whether the marker
gene was expressed in the β-Gal labeled cells that were
expressing the construct; this would indicate a cell autonomous
effect on gene expression. Second, embryos were scored for the
size of the domain of marker gene expression; this would
indicate whether a particular pool of cells was altered.
Increasing Rx1 levels at either stage 12 or 16 resulted in an
initial (stage 20) repression of both RSC markers (pax6, six3;
Table 1). The expression domains were smaller (Figs. 6A, C)
and both genes were repressed in β-Gal labeled cells (e.g., Fig.
6A inset). The same effects were observed in embryos through
early differentiation stages, albeit with a gradual decrease in
frequency (Table 1). Thus, rx1 appears to both repress pax6 and
six3 autonomously (in β-Gal cells) and to reduce the size of the
pax6+/six3+ RSC pools, as indicated by smaller expression
domains in optic vesicles/cups that are significantly larger in
size (Fig. 4). At stage 38, in which a more mature, though not
fully layered, retina has developed, pax6 or six3 remained
repressed in β-Gal labeled cells in some embryos (e.g., Fig. 6B)
but recovered in others (e.g., Fig. 6D); their expression domains
were similar to controls (Table 1) demonstrating that the effects
are transient. A statistical comparison of the frequency of
repression after increasing Rx1 levels at stage 16 only detected a
more prolonged effect on pax6 at stage 32 and a more transient
effect on six3 (Table 1), indicating that rx1 has a slightly more
persistent effect on pax6 expression.
notch1 and sox2 expression were similarly reduced initially
(stages 20–22) in β-Gal labeled cells (Fig. 6E inset) and their
domains were smaller (Table 1; Figs. 6E, G). Thus, rx1
autonomously repressed the expression of these genes, reducing
the pool of cells that had acquired a neural identity. These
effects decreased in frequency at later stages (Table 1). When
Rx1 levels were increased at stage 12, the effects on notch1 and
sox2 expression were restored to normal in the majority of
embryos by stage 38 (Figs. 6F, H). A similar trend was seen
when Rx1 levels were increased at stage 16, but for both genes
the effects were more transient (Table 1), suggesting that by
stage 16 many cells had already acquired neural identity. Thus,
increased Rx1 levels appear to initially delay the acquisition of
neural identity/stem cell gene expression, and the rapid recovery
suggests that this effect may only occur during the develop-
mental window between neural plate and optic cup.
Markers of neural differentiation were analyzed starting at
stage 25, when they are first detectable in the developing retina.
Increasing Rx1 levels at either stage strongly repressed all four
markers at stages 25–32, including both expression domain size
(Figs. 6I, K, M, O) and in β-Gal labeled cells (e.g., Fig. 6I inset;
Table 1). The frequency of repression was reduced by stage 38
for all four genes (Table 1) but was still detectable in β-Gal
labeled cells (Figs. 6J, L, N, P). Thus, increasing Rx1 levels at
early or late neural plate stages repressed both the onset of
differentiation and the size of the pool of differentiating cells.
This appears to be independent of neural identity expression
because after stage 16 activation of Rx1-GR, notch1 and sox2
expression are nearly recovered whereas differentiation genes
are still strongly reduced.
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upstream regulator of pax6 (Zuber et al., 2003), decreasing rx1
target gene activation by Rx1EnR-GR beginning at either stage
did not alter the expression of either RSC or neural stem/identity
markers in β-Gal labeled cells (Table 1; e.g., Fig. 7E inset). The
expression domains of these genes all were smaller (Figs. 7A,
C, E, G), as expected because the optic vesicle and retina were
smaller (Fig. 4). In embryos in which rx1 loss-of-function was
activated at stage 12, the reduction in expression domain size at
stage 38 was less severe for all genes except sox2, consistent
with the less severe reduction in retinal volume compared to
optic cup (Fig. 4). Further, β-Gal labeled cells expressed the
RSC and neural stem/identity markers (Figs. 7B, D, F, H).
These results demonstrate that rx1 activity after the initial
formation of the eye field is not required for the maintenance of
other RSC markers or for the acquisition of neural identity.
Activating Rx1EnR-GR at either stage reduced the expres-
sion domains of all four differentiation markers (Table 1; Figs.
7I, K, M, N). Although the decrease in expression domain size
for all markers was probably the result of a smaller optic vesicle
and retina (Fig. 4), repression also was observed surrounding β-
Gal cells (e.g., insets in Figs. 7M, O). This repression in β-Gal
cells was detectable for all four differentiation markers at stage
38 (Figs. 7J, L, N, P), but the frequency was reduced (Table 1).
For ngn1 and p27, this cellular repression was dramatic at
stages 25 and 32; expression recovered in the majority of
embryos by stage 38 when Rx1EnR-GR was activated at stage
12 but continued to be significantly repressed when activated at
stage 16 (Table 1). For neuroD, cellular repression was greatly
reduced by stage 38 after rx1 loss-of-function at either stage.
For Xath5, the frequency of repression was only moderate at all
stages after Rx1EnR-GR activation at stage 12, whereas it was
dramatic at all stages after Rx1EnR-GR activation at stage 16.
Since the β-Gal cells express RSC and neural identity genes,
these results support the hypothesis that rx1 expression is
required for RSCs/RPCs to initiate differentiation. The more
dramatic repression of differentiation markers after stage 16 rx1
loss-of-function indicates that rx1 becomes more integral to
differentiation at late neural plate stages.
Pax6 also promotes proliferation, but differentially affects
neural identity and differentiation markers
Previous studies showed that increasing Pax6 levels results
in ectopic eye tissue, whereas repressing Pax6 activity in
knockout mice or by expression at blastomere stages of a
dominant-negative construct in Xenopus results in the formation
of a small eye (Hill et al., 1991; Chow et al., 1999; Kenyon et
al., 2001). These results suggest that pax6 establishes and/or
maintains RSCs. Similar to rx1, increasing Pax6 levels
significantly increased the mitotic index of the injected clone
(Fig. 4A). Concordantly, the optic cup and mature retina were
significantly larger than controls (Figs. 4B, C). pax6 loss-of-
function significantly reduced the mitotic index and reduced the
size of the optic vesicle and mature retina (Figs. 4A–C). The
changes in retinal size were less severe in the mature retina
suggesting that the effect is attenuated over time. These findingsindicate that pax6 also is necessary and sufficient to expand the
proliferative pool of cells from optic vesicle stages throughout
retinogenesis; thus, it has a function redundant with rx1.
To determine whether increasing Pax6 levels at eye field
stages affects stem cell and/or differentiating populations, over-
expression studies were performed as above. The domain of rx1
expression was larger transiently after Pax6-GR activation at
stage 12 (Fig. 8A), likely due to the increased size of the
developing retina (Fig. 4), whereas the six3 domain did not
change (Fig. 8C), suggesting that rx1- and six3-expressing
RSCs are differentially expanded by pax6 in the early eye field.
When Pax6-GR was activated at stage 16, both rx1 and six3
domains were transiently decreased (Table 2), suggesting that
pax6-expressing RSCs were promoted at the expense of rx1-
and six3-expressing RSCs. At no stage did β-Gal labeled cells
show repression of rx1 or six3 (Table 2; Figs. 8B, D);
expression was neither repressed when β-Gal labeled cells
were located in regions of endogenous staining nor ectopically
expressed when β-Gal cells were located outside those regions.
Expression domains of neural identity genes were differen-
tially affected after increasing Pax6 levels (Table 2; Figs. 8E–
H). notch1 expression did not change except for the initial and
transient decrease in domain size after the activation of Pax6-
GR at stage 16. At no stage did β-Gal labeled cells show
repression of notch1 (Table 2; Fig. 8F). However, sox2
expression was repressed after Pax6-GR activation at stage
12; this effect was strongest at stage 20 and greatly reduced by
stage 38 (Table 2; Fig. 8G). Interestingly, the opposite effect
was observed after Pax6-GR activation at stage 16; patches of
ectopic sox2 expression surrounding β-Gal labeled cells outside
the retina were observed at all stages (Table 2; Fig. 8H). This
latter effect is consistent with the report that pax6 expression
can promote the formation of neural ectoderm (Grindley et al.,
1995). These data demonstrate a time-dependent effect on sox2
by increased levels of Pax6. Early Pax6-GR activation appears
to delay the transition to a neural RPC, whereas later activation
promotes neural identity. These effects are independent of
notch1 expression.
Similar to rx1, activation of Pax6-GR at either stage 12 or
stage 16 repressed all four markers of differentiation (Table 2).
Increasing Pax6 levels at stage 12 strongly repressed ngn1 and
p27 domains (Figs. 8I, K) and this effect persisted in β-Gal
labeled cells through stage 38 (Figs. 8J, L). In contrast, neuroD
and Xath5 were repressed in only about half of the embryos
(e.g., Figs. 8M, O), and this effect declined considerably by
stage 38 (Table 2). However, when repression was noted, it
occurred in β-Gal labeled cells (Figs. 8N, P). Increasing Pax6
levels at stage 16 also repressed both ngn1 and p27, but the
effect recovered by stage 38 (Table 2). Both neuroD and Xath5
expression were more highly repressed by increasing Pax6
levels at stage 16 and this persisted through stage 38. These
results demonstrate differential temporal effects of increasing
Pax6 on the genes known to regulate the initiation of diffe-
rentiation. The earliest expressed differentiation genes (ngn1,
p27) were repressed more strongly by Pax6-GR activation at
stage 12, whereas the later expressed differentiation genes
(neuroD, Xath5) were repressed more strongly by Pax6-GR
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velopmental times is likely to differentially affect RPCs and
later cell phenotypes.
Although some previous studies suggest that pax6 is an
upstream regulator of rx1 and six3 (Chow et al., 1999), pax6
loss-of-function by activating the dnPax6 protein at either stage
12 or stage 16 neither repressed nor caused ectopic expression
of either RSC marker (Table 2). Although their expression
domains were smaller (Fig. 9A, C), this probably was due to thesmaller size of the retina (Fig. 4). At no stage did β-Gal labeled
cells show repression of rx1 or six3 (Figs. 9B, D). The
expression domain of notch1 was normal after stage 12
treatment (Fig. 9E) but reduced after stage 16 treatment
(Table 2), whereas sox2 was reduced at both (Fig. 9G; Table
2). But at no stage did β-Gal labeled cells show repression of.
notch1 or sox2 (Table 2, Fig. 9E inset, F, H). These results
demonstrate that after initial eye field formation neither RSC
nor neural identity genes require pax6.
Table 1
Changes in marker gene expression after altering Rx1 levels/activity
Marker Cells marked Stage Rx1-GR (St. 12) Rx1-GR (St. 16) Rx1EnR-GR (St. 12) Rx1EnR-GR (St. 16)
Expression (n) Domain (n) Expression (n) Domain (n) Expression (n) Domain (n) Expression (n) Domain (n)
pax6 Retinal stem cells 20 ↓ 90% (28) ↓ 89% (28) ↓ 89% (19) ↓ 89% (19) NC (21) ↓ 65% (21) NC (20) ↓ 80% (20)
25 ↓ 74% (22) ↓ 82% (22) ↓ 67% (21) ↓ 67% (21) NC (19) ↓ 53% (19) NC (16) ↓ 56% (16)
32 ↓ 40% (41) ↓ 76% (41) ↓ 57% (21)⁎ ↓ 57% (21) NC (14) ↓ 64% (14) NC (19) ↓ 70% (19)
38 ↓ 14% (22) ↓ 13% (22) ↓ 17% (12) ↓ 17% (12) NC (21) ↓ 33% (21) NC (18) ↓ 11% (18)
six3 Retinal stem cells 20 ↓ 75% (30) ↓ 93% (30) ↓ 75% (20) ↓ 80% (20) NC (23) ↓ 57% (23) NC (20) ↓ 90% (20)
25 ↓ 67% (18) ↓ 72% (18) ↓ 75% (20) ↓ 75% (20) NC (21) ↓ 50% (21) NC (20) ↓ 80% (20)
32 ↓ 53% (20) ↓ 55% (20) ↓ 11% (19)* ↓ 11% (19) NC (14) ↓ 14% (14) NC (20) ↓ 75% (20)
38 ↓ 5% (19) ↓ 6% (19) ↓ 10% (20) ↓ 10% (20) NC (20) ↓ 10% (20) NC (20) ↓ 60% (20)
notch1 Neural stem cells 20 ↓ 77% (22) ↓ 77% (22) ↓ 50% (20) ↓ 50% (20) NC (20) ↓ 55% (20) NC (20) ↓ 87% (20)
25 ↓ 74% (23) ↓ 82% (23) NC (21)* ↓ 32% (21) NC (21) ↓ 62% (21) NC (19) ↓ 97% (19)
32 ↓ 52% (39) ↓ 67% (39) NC (20)* ↓ 10% (20) NC (14) ↓ 14% (14) NC (20) ↓ 90% (20)
38 NC (23) NC (23) NC (20) NC (20) NC (20) ↓ 10% (20) NC (20) ↓ 60% (20)
sox2 Neural stem cells 20 ↓ 75% (43) ↓ 91% (43) ↓ 90% (20)* ↓ 93% (20) NC (19) ↓ 84% (19) NC (20) ↓100% (20)
25 ↓ 67% (21) ↓ 67% (21) ↓ 35% (20) ↓ 75% (20) NC (21) ↓ 95% (21) NC (20) ↓ 85% (20)
32 ↓ 56% (39) ↓ 63% (39) ↓ 20% (20)* ↓ 30% (20) NC (20) ↓ 85% (20) NC (20) ↓ 90% (20)
38 ↓ 24% (36) ↓ 25% (36) ↓ 10% (20) ↓ 10% (20) NC (17) ↓ 88% (17) NC (18) ↓ 78% (18)
ngn1 Differentiating
neurons
20 – – – – – – – –
25 ↓ 90% (42) ↓ 90% (42) ↓ 86% (20)* ↓ 84% (20) ↓ 90% (20) ↓ 90% (20) ↓ 90% (21) ↓ 90% (21)
32 ↓ 90% (20) ↓ 70% (20) ↓ 71% (20) ↓ 70% (20) ↓ 89% (19) ↓ 79% (19) ↓ 82% (20) ↓ 82% (20)




20 – – – – – – – –
25 ↓ 83% (36) ↓ 86% (36) ↓ 79% (19) ↓ 84% (19) ↓ 78% (23) ↓ 96% (23) ↓ 88% (18) ↓ 88% (18)
32 ↓ 88% (18) ↓ 88% (18) ↓ 83% (30) ↓ 80% (30) ↓ 89% (35) ↓ 89% (35) ↓ 86% (24) ↓ 86% (24)
38 ↓ 10% (20) ↓ 10% (20) ↓ 44% (18)* ↓ 44% (18) ↓ 29% (28) ↓ 64% (28) ↓ 72% (18)* ↓ 72% (18)
neuroD Differentiating
neurons
20 – – – – – – – –
25 ↓ 70% (20) ↓ 85% (20) ↓ 90% (21) ↓ 81% (21) ↓ 60% (20) ↓ 84% (20) ↓ 84% (13) ↓ 84% (13)
32 ↓ 73% (11) ↓ 73% (11) ↓ 76% (19) ↓ 84% (19) ↓ 30% (15) ↓ 20% (15) ↓ 85% (20)* ↓ 50% (20)
38 ↓ 64% (11) ↓ 14% (11) ↓ 70% (20) ↓ 70% (20) ↓ 35% (20) ↓ 35% (20) NC (24)* ↓ 67% (24)
Xath5 Differentiating
neurons
20 – – – – – – – –
25 ↓ 61% (18) ↓ 79% (14) ↓ 85% (20) ↓ 85% (20) ↓ 47% (17) ↓ 47% (17) ↓ 94% (18)* ↓ 94% (18)
32 ↓ 60% (15) ↓ 60% (15) ↓ 64% (22) ↓ 64% (22) ↓ 40% (15) ↓ 40% (15) ↓ 95% (20)* ↓ 95% (20)
38 ↓ 10% (15) ↓ 10% (15) ↓ 37% (19) ↓ 37% (19) ↓ 47% (19) ↓ 47% (19) ↓ 89% (19)* ↓ 89% (19)
The percentage of embryos showing an effect on marker gene expression in β-Gal labeled cells (Expression), and the percentage of embryos showing an effect on the
size the marker gene expression domain (Domain) is shown for each stage analyzed. ↓ indicates decreased expression or smaller domain; NC indicates no change in
expression or domain size; – indicates that analysis was not done at that stage because the gene is not yet expressed in the developing retina. Numbers in parentheses
denote sample size.
⁎ Indicates significant difference compared to stage 12 (p<0.01).
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pax6 loss-of-function at eye field stages and these effects varied
with the onset of the loss (Table 2). When Pax6 activity was
reduced at stage 12, ngn1 expression was reduced in allFig. 5. Normal expression of stem cell (rx1, pax6, six3), neural identity (notch1, sox
Embryos injected with β-gal mRNA were processed by in situ hybridization to de
embryos are external views of whole-mount preparations [bars=100 μm]; all stage 3
internal expression patterns [bar=20 μm]. (A) Summary of the expression domains o
Perron and Harris (1999), Ohnuma et al. (1999) and our results. All genes except ngn
six3 and sox2 are expressed in all zones of the CMZ. Other genes are expressed only
contain RPCs. Within the stage 38 central retina, these genes are differentially expre
throughout the optic cup (arrow). (C) At stage 38, rx1 is expressed in all zones of the C
cup (arrow). (E) At stage 38, pax6 is expressed in the CMZ and throughout the GCL
six3 is expressed throughout the CMZ, and in the GCL and INL; the faint staining in t
the optic vesicle (arrow). (I) At stage 38, notch1 is expressed in zones 2 and 3 of the C
vesicle (arrow). (K) At stage 38, sox2 is expressed in all zones of the CMZ, strongly i
part of the optic cup (arrow). (M) At stage 38, ngn1 is expressed in all layers of the cen
cup (arrow). (O) At stage 38, p27 is expressed in zones 2 and 3 of the CMZ and throug
(Q) At stage 38, neuroD is expressed in zone 3 of the CMZ and throughout the GCL a
Xath5 is expressed in zone 3 of the CMZ and throughout the GCL and INL.embryos (Fig. 9I); this effect recovered somewhat by stage 38
but β-Gal labeled cells often repressed ngn1 expression (Fig.
9J). When Pax6 activity was reduced at stage 16 there was a less
dramatic repression of ngn1 that recovered more rapidly (Table2) and differentiation (ngn1, p27, neuroD, Xath5) markers in control embryos.
termine the normal expression pattern of each marker gene. All stages 22–27
8 views are from whole mount preparations that were thickly sectioned to reveal
f marker genes at stage 38 in the different layers of the retina, based on data from
1 are expressed in some part of the ciliary marginal zone (CMZ). Only pax6, rx1,
in the zones of the CMZ (2, 3) closest to the central retina, which are thought to
ssed in the three cellular layers (GCL, INL, ONL). L, lens. (B) rx1 is expressed
MZ and weakly in the ONL (arrow). (D) pax6 is expressed throughout the optic
and INL. (F) six3 is expressed throughout the optic cup (arrow). (G) At stage 38,
he ONL is due to the thickness of the section. (H) notch1 is expressed throughout
MZ and throughout the GCL and INL. (J) sox2 is expressed throughout the optic
n the GCL and is barely detected in the INL. (L) ngn1 is expressed in the central
tral retina, and is absent from the CMZ. (N) p27 is expressed broadly in the optic
hout the GCL and INL. (P) neuroD is expressed broadly in the optic cup (arrow).
nd INL. (R) Xath5 is expressed broadly in the optic cup (arrow). (S) At stage 38,
Fig. 6. Increasing Rx1 levels at stage 12 represses stem cell, neural identity and differentiation marker genes. (A) pax6 expression domain in the optic vesicle is smaller
(arrow), and repressed in β-Gal labeled cells (inset, arrowheads). (B) In a small percentage of stage 38 embryos, pax6 expression is repressed in β-Gal labeled cells
(arrowheads). (C) six3 expression domain in the optic vesicle is smaller (arrow). (D) In most stage 38 embryos, six3 expression is normal in β-Gal labeled cells
(arrowheads). (E) notch1 expression domain in the optic vesicle is smaller (arrow), and repressed in β-Gal labeled cells (inset, arrowheads). (F) By stage 38 there is no
repression surrounding β-Gal-labeled nuclei (arrowheads). (G) sox2 expression domain in the optic vesicle is smaller (arrow). (H) By stage 38 there is no repression
surrounding β-Gal-labeled nuclei (arrowheads). (I) ngn1 expression in the optic cup (arrow) is fainter (cf. Fig. 5L) and repressed in β-Gal labeled cells (inset,
arrowheads). (J) At stage 38, ngn1 expression continues to be repressed surrounding β-Gal-labeled nuclei (arrowheads). (K) p27 expression in the optic cup (arrow) is
fainter (cf. Fig. 5N). (L) At stage 38, p27 expression continues to be repressed surrounding β-Gal-labeled nuclei (arrowheads) in some embryos. (M) neuroD
expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5P). (N) At stage 38, neuroD continues to be repressed surrounding β-Gal labeled nuclei (arrowheads).
(O) Xath5 expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5R). (P) At stage 38, Xath5 expression continues to be repressed surrounding β-Gal-labeled
nuclei (arrowheads) in some embryos. Data for stage 16 activation are similar. Dashed lines indicate the outline of the retinas in the sectioned material. For whole
mounts, bars=100 μm; for sections bars=20 μm.
232 N.A. Zaghloul, S.A. Moody / Developmental Biology 306 (2007) 222–2402). Similar effects were observed for p27 expression (Table 2;
Figs. 9K–L). In contrast, reduced Pax6 activity at either stage
12 or stage 16 had no observable effect on neuroD expression in
β-Gal labeled cells, even though the expression domain was
transiently smaller (Table 2; Figs. 9M–N). The domain of
Xath5 and its expression in β-Gal labeled cells were reduced in
less than half the embryos when Pax6 activity was reduced at
stage 12 and the effect recovered by stage 38 (Table 2, Figs.
9O–P). However, when Pax6 activity was reduced at stage 16
Xath5 expression was profoundly and persistently reduced
(Table 2). These results demonstrate that the expression ofngn1, p27 and Xath5 require pax6 during different windows of
eye field stages (ngn1, p27 earlier; Xath5 later), whereas
expression of neuroD is independent of pax6.
Discussion
The retina provides a useful model in which to study the
specification of neural cell types. Its limited number of cells that
differentiate in a fixed temporal sequence and spatial pattern has
facilitated studies of cell fate specification. Much work has
focused on the geneticmechanisms that direct cell differentiation
Fig. 7. rx1 is not required after stage 12 for other retinal stem or neural identity marker genes but is necessary for the onset of differentiation markers. (A) pax6
expression domain in the optic vesicle (arrow) is smaller (cf. Fig. 5D). (B) At stage 38, the pax6 expression domain is normal, and no repression surrounds β-Gal-
labeled nuclei (arrowheads). (C) six3 expression domain in the optic vesicle (arrow) is smaller (cf. Fig. 5F). (D) At stage 38, there is no repression of six3 surrounding
the β-Gal-labeled nuclei (arrowheads). (E) notch1 expression domain in the optic vesicle is smaller (arrow). However, cells with β-Gal labeled nuclei (inset,
arrowheads) express notch1. (F) At stage 38, notch1 expression is similar to controls and no repression surrounds β-Gal labeled nuclei (arrowheads). (G) sox2
expression domain in optic vesicle (arrow) is smaller (cf. Fig. 5J). (H) At stage 38, there is no repression of sox2 expression surrounding the β-Gal labeled nuclei
(arrowheads). (I) ngn1 expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5L). (J) At stage 38, ngn1 expression continues to be repressed surrounding β-
Gal labeled nuclei (arrowheads). (K) p27 expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5N). (L) At stage 38, p27 expression is repressed surrounding
β-Gal labeled nuclei (arrowheads) in some embryos. (M) neuroD expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5P). Inset: cells with β-Gal-labeled
nuclei (arrowheads) do not express neuroD. (N) At stage 38, neuroD expression continues to be repressed in β-Gal-labeled cells (arrowheads). (O) Xath5 expression
in the optic cup (arrow) is greatly reduced (cf. Fig. 5R). Inset: cells with β-Gal-labeled nuclei (arrowheads) do not express Xath5. (P) At stage 38, Xath5 continues to
be repressed in β-Gal-labeled cells (arrowheads). Data for stage 16 activation are similar albeit at higher frequencies for differentiation genes (see Table 1). Dashed
lines indicate the outline of the retinas in the sectioned material. For whole mounts, bars=100 μm; for sections bars=20 μm.
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(reviewed in Hatakeyama and Kageyama, 2004), but little is
known about how earlier events affect this process. rx1 and pax6
are both expressed at the initial formation of the eye field and are
crucial for the production of the retinal stem cells (RSCs); loss-
of-function of either results in severe eye defects and increased
expression of either causes ectopic retinal tissue. However, both
genes continue to be expressed as cells begin to differentiate and
populate the different retinal layers, suggesting that they have
additional roles in cell type specification. Because these twogenes are highly expressed during neural plate stages, when
biased progenitors are forming (Moody et al., 2000), we sought
to determine whether these two key regulators of retinogenesis
have differential roles in this initial period of cell type
specification. This was accomplished by both increased expres-
sion and loss-of-function using hormone-inducible gene con-
structs in order to bypass the critical time period in which rx1 and
pax6 are both required to establish the eye field.
Analyzing changes in the number of specific cell types
representing each retinal layer, produced by the genetically
Fig. 8. Increasing Pax6 levels at stage 12 does not alter stem cell marker genes but represses sox2 and differentiation marker genes. (A) rx1 expression in the optic
vesicle (arrowhead) is larger (cf. Fig. 5B). (B) At stage 38, rx1 expression is similar to controls and no repression surrounds β-Gal-labeled nuclei (arrowheads). (C)
six3 expression in the optic vesicle (arrowhead) is not different from the control side. (D) At stage 38, no repression of six3 expression surrounds β-Gal-labeled nuclei
(arrowhead). (E) notch1 expression in the optic vesicle on the injected side (arrowhead) is similar to the control side. (F) At stage 38, no repression of notch1
expression surrounds β-Gal-labeled nuclei (arrowheads). (G) When Pax6-GR protein is activated at stage 12, the sox2 expression domain in the optic vesicle is smaller
(arrow). (H) When Pax6-GR protein is activated at stage 16, sox2 expression in the optic vesicle domain is smaller (arrow), but in the neural plate (np) it is broader and
is ectopically expressed (arrow, inset). (I) ngn1 expression in the optic cup (arrowhead) is fainter and reduced in size (cf. Fig. 5L). (J) At stage 38, repression of ngn1 in
β-Gal labeled cells persists (arrowheads). (K) p27 expression in the optic cup (arrowhead) is fainter and reduced in size (cf. Fig. 5N). (L) At stage 38, repression of p27
expression in β-Gal labeled cells (arrowheads) persists. (M) neuroD expression in the optic cup is fainter and reduced in size (cf. Fig. 5P). (N) At stage 38, neuroD
expression remains repressed (arrowheads) in only a small number of embryos (Table 2). (O) Xath5 expression in the optic cup (arrow) is fainter and reduced in size
(cf. Fig. 5R). (P) At stage 38, Xath5 expression remains repressed in β-Gal labeled cells (arrowhead) in a small number of embryos (Table 2). Data for stage 16
activation (except for sox2, see H above) are similar albeit at significantly lower frequencies at stage 38 for ngn1 and p27 and at higher frequencies for neuroD and
Xath5 (Table 2). Dashed lines indicate the outline of the retinas in the sectioned material. For whole mounts, bars=100 μm; for sections bars=20 μm.
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because it broadly affected all cell types, whereas pax6 regulates
retinal progenitor cell (RPC) specification because it selectively
affected different cell types in a time-dependent manner (Fig.
10). Analyzing the effects of increasing Rx1 and Pax6 levels or
decreasing their activity on proliferation and the expression of
RSC, neural identity and differentiation marker genes demon-
strate that rx1 promotes proliferation, represses other RSC genes
as well as neural identity and differentiation marker genes.
Although pax6 also promotes proliferation, it does not affect theother RSC genes or notch1, but represses sox2 and differentia-
tion genes. Thus, these two genes have similar but not identical
roles in regulating the early steps of retinal cell fate.
rx1 establishes and maintains retinal stem cells
rx1 is necessary for the formation of the eye, probably as a
result of its role in establishing the definitive RSCs. In Xenopus,
strong rx1 expression is initially detected at stage 12 when the
eye field is established, but weak expression can be detected
Table 2
Changes in marker gene expression after altering Pax6 levels/activity
Marker Cells marked Stage Pax6-GR (St. 12) Pax6-GR (St. 16) dnPax6-GR (St. 12) dnPax6-GR (St. 16)
Expression (n) Domain (n) Expression (n) Domain (n) Expression (n) Domain (n) Expression (n) Domain (n)
rx1 Retinal stem cells 20 NC (10) ↑ 80% (10) NC (19) ↓ 95% (19) NC (20) ↓ 60% (20) NC (18) ↓ 89% (18)
25 NC (20) ↑ 61% (20) NC (19) NC (19) NC (20) ↓ 50% (20) NC (19) ↓ 58% (19)
32 NC (15) ↑ 45% (15) NC (16) NC (16) NC (22) ↓ 45% (22) NC (19) ↓ 63% (19)
38 NC (21) ↑ 10% (21) NC (19) NC (19) NC (17) NC (17) NC (17) ↓ 35% (17)
six3 Retinal stem cells 20 NC (18) NC (18) NC (17) ↓ 78% (17) NC (23) ↓ 83% (23) NC (21) ↓ 95% (21)
25 NC (19) NC (19) NC (16) NC (16) NC (14) ↓ 71% (14) NC (18) ↓ 100% (18)
32 NC (23) NC (23) NC (19) NC (19) NC (15) ↓ 60% (15) NC (17) ↓ 100% (17)
38 NC (19) NC (19) NC (16) NC (16) NC (13) ↓ 91% (13) NC (15) ↓ 100% (15)
notch1 Neural stem cells 20 NC (23) NC (23) NC (15) ↓ 53% (15) NC (20) NC (20) NC (18) ↓ 50% (18)
25 NC (20) NC (20) NC (16) NC (16) NC (22) NC (22) NC (20) ↓ 47% (20)
32 NC (11) NC (11) NC (15) NC (15) NC (21) NC (21) NC (20) ↓ 17% (20)
38 NC (19) NC (19) NC (12) NC (12) NC (13) NC (13) NC (18) NC (18)
sox2 Neural stem cells 20 ↓ 62% (40) ↓ 71% (40) ↑ 55% (18)⁎ ↑ 55% (18) NC (37) ↓ 57% (37) NC (18) ↓ 88% (18)
25 ↓ 48% (31) ↓ 67% (31) ↑ 50% (20)* ↑ 50% (20) NC (30) ↓ 9% (30) NC (20) ↓ 76% (42)
32 ↓ 27% (39) ↓ 21% (39) ↑ 75% (20)* ↑ 75% (20) NC (33) ↓ 9% (33) NC (21) ↓ 18% (34)
38 ↓ 9% (39) NC (17) ↑ 82% (17)* ↑ 82% (17) NC (45) ↓ 4% (45) NC (20) NC (20)
ngn1 Differentiating neurons 20 – – – – – – – –
25 ↓ 90% (20) ↓ 90% (20) ↓ 87% (20) ↓ 88% (20) ↓ 100% (19) ↓100% (19) ↓ 61% (18)* ↓ 61% (18)
32 ↓ 89% (19) ↓ 89% (19) ↓ 82% (23) ↓ 82% (23) ↓ 100% (20) ↓100% (20) ↓ 46% (33)* ↓ 46% (33)
38 ↓ 89% (18) ↓ 89% (18) ↓ 18% (11)* ↓ 18% (11) ↓ 55% (20) ↓ 55% (20) NC (17)* NC (17)
p27 Differentiating neurons
(cell cycle exit)
20 – – – – – – – –
25 ↓ 84% (32) ↓ 76% (32) ↓ 84% (19) ↓ 89% (19) ↓ 80% (15) ↓ 80% (15) ↓ 50% (20)* ↓ 72% (20)
32 ↓ 70% (18) ↓ 70% (18) ↓ 47% (19) ↓ 47% (19) ↓ 60% (15) ↓ 60% (15) NC (38)* ↓ 72% (38)
38 ↓ 77% (13) ↓ 77% (13) ↓ 11% (18)* NC (18) ↓ 55% (20) ↓ 50% (20) NC (38)* NC (38)
neuroD Differentiating neurons 20 – – – – – – – –
25 ↓ 42% (18) ↓ 42% (18) ↓ 98% (18)* ↓ 95% (18) NC (20) ↓ 74% (20) NC (31) ↓ 69% (31)
32 ↓ 50% (13) ↓ 50% (13) ↓ 75% (18) ↓ 54% (18) NC (20) ↓ 50% (20) NC (30) ↓ 45% (30)
38 ↓ 27% (15) ↓ 27% (15) ↓ 79% (18)* ↓ 76% (18) NC (21) NC (21) NC (19) NC (19)
Xath5 Differentiating neurons 20 – – – – – – – –
25 ↓ 58% (18) ↓ 58% (18) ↓ 67% (19) ↓ 70% (19) ↓ 42% (19) ↓ 42% (19) ↓ 91% (23)* ↓ 91% (23)
32 ↓ 58% (13) ↓ 58% (13) ↓ 40% (20) ↓ 40% (20) ↓ 40% (20) ↓ 40% (20) ↓100% (23)* ↓ 100% (23)
38 ↓ 19% (15) ↓ 19% (15) ↓ 75% (18)* ↓ 80% (18) NC (19) NC (19) ↓ 75% (19)* ↓ 75% (19)
The percentage of embryos showing an effect on marker gene expression in β-Gal labeled cells (Expression), and the percentage of embryos showing an effect on the
size of the marker gene expression domain (Domain) is shown for each stage analyzed. ↓ indicates decreased expression or reduced domain size; ↑ indicates ectopic
expression or increased domain size; NC indicates no change in expression or domain size; – indicates that analysis was not done at that stage because the gene is not
yet expressed in the developing retina. Numbers in parentheses denote sample size.
⁎ Indicates significant differences compared to stage 12 (p<0.01).
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2000; Zuber et al., 2003). This suggests that rx1 is present prior
to eye field formation, and perhaps directs the genetic pathway
involved in that process. When rx1 is inactivated in mouse prior
to gastrulation, there are severe eye defects or no eyes develop,
indicating that rx1 plays a key role in establishing the multi-
potent RSCs that comprise the eye field. The maintenance of
rx1 expression throughout eye field, optic vesicle and optic
cup stages, when different RPCs are being produced, and in the
CMZ in the differentiating retina suggests that rx1 plays an
additional role in maintaining an RSC pool during retinogen-
esis. Our observations that increased Rx1 levels during neural
plate stages increased proliferation and the size of the retina, and
decreased Rx1 activation of target genes had the opposite effect,
support this interpretation.
However, the observation that rx1 also is expressed in
differentiated ONL and OINL cells suggests that it plays an
additional later role in the specification of these cell types. To
distinguish which of these latter two roles are in play during eye
field stages, it is necessary to be able to manipulate geneexpression after the establishment of the RSCs. Utilizing
hormone-inducible rx1 constructs demonstrated that increased
Rx1 levels at either early or late neural plate stages repressed or
delayed the differentiation of representative cell types in each of
the retinal layers (data herein and Zaghloul and Moody, 2007).
Conversely, rx1 loss-of-function at neural plate stages increased
the numbers or promoted the differentiation of 3 of the 4 cell
types monitored. These results are consistent with a report that
overexpression of rx1 in optic cup cells by DNA transfection
results in the production of all cell types, indicating a role for
rx1 in maintaining multipotency (Casarosa et al., 2003).
Together these studies indicate that rx1 plays a key role in
maintaining RSCs in a proliferative, multipotent stem state at
least through optic cup stages. To determine whether rx1 has a
later role in determining ONL and OINL fates new methods for
controlling the temporal expression of constructs are needed, as
hormones do not penetrate the Xenopus embryo very well once
the neural tube closes.
If rx1 is the initial regulatory gene in the RSC pathway, and
its increased expression maintains cells in the RSC state, then
Fig. 9. pax6 is not required after stage 12 for other retinal stem cell or neural identity marker genes but is necessary for some differentiation markers. (A) rx1 expression
domain in the optic vesicle is smaller (arrow). (B) At stage 38, rx1 expression is similar to controls and no repression surrounds β-Gal-labeled nuclei (arrowheads). (C)
six3 expression domain in the optic vesicle is smaller (cf. Fig. 5F). (D) At stage 38, no repression of six3 surrounds β-Gal-labeled nuclei (arrowheads). (E) notch1
expression domain in the optic vesicle (arrow) does not change, and β-Gal labeled cells (red) express notch1 (inset). (F) At stage 38, no repression of notch1
expression surrounds β-Gal labeled cells (arrowheads). (G) sox2 expression domain in the optic vesicle is smaller (arrow). (H) At stage 38, no repression of sox2
expression surrounds β-Gal-labeled nuclei (arrowheads). (I) ngn1 expression in the optic cup (arrow) is fainter (cf. Fig. 5L). (J) At stage 38, ngn1 continues to be
repressed surrounding β-Gal labeled nuclei (arrowhead). (K) p27 expression in the optic cup (arrow) is fainter (cf. Fig. 5N). (L) At stage 38, p27 expression continues
to be repressed surrounding clusters of β-Gal labeled nuclei (arrowheads). (M) neuroD expression domain in the optic cup (arrow) is reduced in size but not expression
intensity (cf. Fig. 5P). (N) At stage 38, neuroD expression is not repressed in β-Gal labeled cells (arrowheads). (O) Xath5 expression domain in optic cup (arrow) is
fainter in less than half of the embryos (cf. Fig. 5R). (P) At stage 38, Xath5 expression is not repressed in β-Gal labeled cells (arrowheads). Data for stage 16 activation
are similar, but at significantly different frequencies for differentiation genes (see Table 2). Dashed lines indicate the outline of the retinas in the sectioned material. For
whole mounts, bars=100 μm; for sections bars=20 μm.
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to expand the expression of two other RSC genes, pax6 and
six3. However, increasing Rx1 levels represses these two
genes, and rx1 loss-of-function indicates that their expression is
independent of rx1 in RSCs. These results are consistent with
previous studies that show that: (1) loss of rx1 expression in
knockout mice does not affect the initial expression of other
genes expressed in the region of the anterior neural plate that
gives rise to RSCs, including otx2, six3 and pax6 (Zhang et al.,
2000); and (2) rx1 over-expression at blastomere stages results
in a slight repression of otx2, six3 and pax6 (Andreazzoli et al.,1999). Based on previous studies that the expression domains of
rx1, pax6 and six3 overlap but are not identical in the eye field,
and that the eye field contains a heterogeneous pool of
progenitor cells (reviewed in Zaghloul et al., 2005), we propose
that a high level of Rx1 promotes the maintenance of a primitive
RSC, which is proliferative and multipotent, and feeds back on
other RSC marker genes to maintain their expression at lower
levels (Fig. 10). Consistent with this model, increased Rx1
levels at neural plate stages also represses downstream effectors
of differentiation. The expression of two neural identity
markers, notch1 and sox2, was delayed; these genes maintain
Fig. 10. Proposed differential functions of Rx1 and Pax6 during early steps in
retinal development. High levels of Rx1 maintain the retinal stem cell (RSC) in a
primitive, proliferative, multipotential state. As levels of Rx1 are reduced, the
RSC becomes more restricted and when the levels of other RSC genes (Pax6,
Six3) differentially rise, RSCs transition to become retinal progenitor cells
(RPCs). The onset of expression of neural identity genes (e.g., Sox2, Notch1)
creates RPCs that are biased to a neural fate; differential expression levels of
these genes may create different subtypes of biased RPCs. Our data indicate that
after the formation of the eye field, continued high levels of Rx1 at stage 12
maintain primitive RSCs and prevent or delay the transition to restricted RSCs.
Continued high levels of Rx1 at stage 16 also promotes primitive RSCs and
reduces the expression of Pax6- and Six3-expressing RPCs. In contrast,
continued high levels of Pax6 at stage 12 reduce the primitive RSCs and
promote restricted RSCs and Pax6-expressing RPCs. These latter cells repress
the expression of Sox2 in biased RPCs. Continued high levels of Pax6 at stage
16 reverse the repression of Sox2 expression.
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of neuronal differentiation genes (Van Raay et al., 2005).
Increased Rx1 levels also repressed the expression of four
different neural differentiation genes, and caused a general
decrease in the production of all monitored cell types,
presumably by decreasing or delaying the onset of differentia-
tion. Together these data support the proposal that elevated
levels of Rx1 promote the maintenance of a primitive multi-
potent, undifferentiated RSC.
There are some differential effects of altered Rx1 levels/
activity on particular cell types that are not simply explained by
prolonged maintenance of primitive RSCs. If rx1-positive
RSCs produce RPCs whose fates are simply defined by the
temporal order of their generation, one would expect that early
manipulation of Rx1 levels would affect all cell types, whereas
later manipulation would primarily affect later born cell types
(cones, amacrines) and spare early born cell types (ganglion,
horizontal). The results from increasing Rx1 levels do not
follow this pattern; one late cell type (amacrine) was profoundly
repressed early (stage 12) and significantly less so later (stage
16). Thus, Rx1 levels may also affect the specification of certain
types of RPCs during neural plate stages. For example, the
RPCs identified in the stage 14/15 neural plate that are biased
towards amacrine and IINL fates (Moody et al., 2000) may be
repressed by increasing Rx1 levels at stage 12 and refractive to
this manipulation by stage 16. Because six3 is thought to be
important in promoting amacrine cell fate (Marquardt et al.,2001; Inoue et al., 2002), it is possible that increased Rx1 levels
repress amacrine fate by repressing six3-positive RSCs/RPCs at
these stages (Fig. 10).
pax6 plays multiple roles in retinal development
pax6 also plays a key role in the establishment of the eye
field. In Xenopus, its initial expression can be strongly detected
at stage 12.5 but weak expression can be detected during
gastrulation (Hirsch and Harris, 1997; Zuber et al., 2003).
Inactivation of pax6 in mice prior to gastrulation represses eye
development (Hill et al., 1991; Grindley et al., 1995), although
it may act downstream of rx1 because pax6 loss-of-function
mutants are less severe (Mathers and Jamrich, 2000). In
addition, pax6 likely maintains RSC and RPC throughout
retinogenesis because it is expressed in these cells in the neural
plate, optic vesicle, optic cup and CMZ. Furthermore, increased
Pax6 levels promote RSC/RPC proliferation and decreased
Pax6 activity reduces proliferation (Fig. 4; Philips et al., 2005).
In addition to its role in establishing the eye field, we propose
that shortly after the formation of the eye field, pax6 promotes
the formation of a restricted RSC subtype (Fig. 10). Like rx1,
increased or decreased Pax6 levels/activity altered proliferation
and the size of the retina, indicating that the pax6-positive cells
are RSCs. But pax6 did not change the expression of the other
RSC genes (rx1, six3), suggesting that the pax6-positive cells
are more restricted than the multipotent rx1-positive primitive
RSCs. Also, altered Pax6 levels/activity had differential effects
on the downstream genes, indicating that the pax6-positive cells
are different from the rx1-positive primitive RSCs. Unlike rx1,
Pax6 does not affect the expression of notch1; this observation
is consistent with the report that notch1 may act upstream of
pax6 (Onuma et al., 2002). When Pax6 levels are increased at
stage 12, sox2 expression is reduced, whereas increasing Pax6
at stage 16 expands sox2 expression. These findings indicate
that during the window between early and late neural plate
stages pax6 plays different roles in regulating sox2-mediated
aspects of neural identity. Because sox2 is necessary for the
maintenance of neural identity and subsequent differentiation of
RPCs (Van Raay et al., 2005), initial repression of sox2 by Pax6
may maintain restricted RSCs and RPCs and delay cells from
becoming biased RPCs (Fig. 10). This interpretation is
consistent with the observation that loss of pax6 in mice leads
to premature retinal differentiation (Philips et al., 2005).
Conversely, the later induction of sox2 expression by pax6
may facilitate the transition from RPC to biased RPC and
subsequent onset of differentiation.
Previous work also indicates that pax6 has a role in spe-
cifying certain cell types. In the differentiating retina, pax6
continues to be expressed in the cells of the IINL and GCL.
Furthermore, eliminating pax6 expression at optic cup stages
depletes the subsequent formation of all cell types except
amacrine cells (Marquardt et al., 2001). Our analyses of cell
types in the differentiated retina also indicate that altered Pax6
levels/activity at neural plate stages affect cell fate specification.
Both horizontal cells and cone photoreceptors, which reside in
the two cell layers (OINL, ONL, respectively) in which pax6 is
238 N.A. Zaghloul, S.A. Moody / Developmental Biology 306 (2007) 222–240not expressed in the mature retina, were repressed by increased
Pax6 levels and expanded by reduced Pax6 activity. Interest-
ingly, the effects on horizontal cells were only apparent when
Pax6 levels were increased at stage 12 and the effects on cone
cells were only apparent when Pax6 levels were increased at
stage 16. This difference in timing correlates with the generation
of horizontal cells earlier than cone cells.
The effects on ganglion cells also are consistent with the
normal expression pattern of pax6 in the GCL. Increasing Pax6
levels at stage 12 promotes ganglion cells, whereas there is no
significant effect at stage 16; this temporal difference may be
due to the fact that ganglion cells are generated first and,
therefore, later manipulations may be less effective. However,
the reduction of Pax6 activity at stage 12 did not affect ganglion
cell numbers, although these cells are lost when pax6 is
eliminated in the optic cup (Marquardt et al., 2001). This
suggests that pax6 loss-of-function at neural plate stages is not
sufficient to eliminate ganglion cells, perhaps due to compensa-
tion by other eye field factors. For example, recent work has
defined a regulatory network of genes that specifies ganglion
cell fate (reviewed in Mu and Klein, 2004). Not only are there
many genes in this pathway that may compensate for each other,
but the proper levels of expression and timing of expression are
likely to be important in producing enough ganglion cells as
well as limiting their numbers.
Consistent with studies showing that knockdown of pax6
during optic cup stages results in the nearly exclusive
production of amacrine cells (Marquardt et al., 2001), reduction
of Pax6 activity at both early and late neural plate stages
resulted in an increase in amacrine cells (Zaghloul and Moody,
2007). Since increased Pax6 levels at either stage did not repress
GABA-positive amacrine cells, which represent approximately
95% of all amacrine cells (Huang and Moody, 1998), it is
unlikely that pax6 specifically represses amacrine cells. It is
more likely that a reduced level of Pax6 activity is permissive
for other factors that promote amacrine cell fate. For example,
Marquardt et al. (2001) also showed that factors involved in
amacrine fate are unaffected by repression of pax6. However, it
is interesting that a small subset of amacrine cells, those that
express DA, are repressed by increasing Pax6 levels during
neural plate stages (Zaghloul and Moody, 2007). Whether there
also are differential effects on the more than 20 different
amacrine subtypes will require further investigation.
The differential effects of altering Pax6 levels/activity in the
neural plate on neural identity and differentiation genes also
indicate a role for this gene in the early steps of cell type
specification. When Pax6 levels were increased at stage 12,
ganglion cell numbers increased, consistent with a previous
report that the repression of sox2 expression in the optic vesicle
results in an increase in ganglion cells (Van Raay et al., 2005).
By stage 16, however, increasing Pax6 levels increased sox2
expression and the ganglion cell numbers were no longer
affected, suggesting that the role of pax6 in ganglion cell fate
via sox2 regulation occurs during a defined temporal window in
the neural plate. We illustrate this as occurring at the transition
between RPC and biased RPC (Fig. 10), but this needs to be
experimentally tested.When Pax6 activity at neural plate stages is decreased,
markers of differentiation are lost with the exception of neuroD.
This is consistent with findings in knockout mice that pax6
expression is necessary for the expression of many differentia-
tion genes but not for neuroD (Marquardt et al., 2001). Thus, the
onset of neuroD expression appears to be independent of pax6
activity. However, the levels of ngn1 and p27 expression were
altered by increasing and decreasing Pax6 levels/activity during
neural plate stages. They were most strongly affected by altered
Pax6 levels/activity at stage 12, whereas Xath5 was most
strongly affected by altered Pax6 levels/activity at stage 16.
Because these different bHLH factors are implicated in the
production of different retinal cell phenotypes, pax6 may
regulate, in a time-dependent manner, the production of different
subtypes of RPCs.
Altering Pax6 levels/activity affected the size of two
neuronal populations, consistent with published effects of
altered neuroD expression. Increased Pax6 levels had no effect
on the number of amacrine cells produced, but pax6 loss-of-
function promoted the formation of amacrine cells (Zaghloul
and Moody, 2007). In mice, pax6 knockout in the optic cup
resulted in continued neuroD expression and the overproduc-
tion of amacrine cells (Marquardt et al., 2001), and neuroD
promotes amacrine cell fate when over-expressed in the
presence of Math3 (Inoue et al., 2002; Morrow et al., 1999).
Thus, neuroD appears to be required for amacrine cell
production, and pax6 appears to limit the size of the amacrine
cell population by repressing neuroD. The regulation of
neuroD by pax6 is also important for photoreceptor specifica-
tion. Misexpression of neuroD in the developing retina results
in the increased production of photoreceptors (Yan and Wang,
1998). In our studies, increasing Pax6 levels at neural plate
stages repressed neuroD and decreased cone photoreceptors.
Decreasing Pax6 activity did not alter neuroD expression and
photoreceptors formed in greater numbers. Thus, Pax6 levels/
activity at neural plate stages play a role in maintaining the
correct size of amacrine and photoreceptor populations in the
retina by regulating neuroD activity.
The effect of pax6 on specification of cell types through
neuroD activity may be related, in part, to effects on ngn1
and Xath5. ngn1 is thought to be upstream of neuroD function
in the photoreceptor pathway (Perron et al., 1999). Increasing
Pax6 levels at either neural plate stage resulted in a repression of
ngn1 expression, and thus might be involved in regulating the
photoreceptor population. However, pax6 loss-of-function
resulted in a reduction of ngn1 expression, indicating that
neither pax6 nor ngn1 expression is necessary for neuroD
promotion of cone photoreceptor differentiation at these stages.
It will be important to investigate whether pax6 has similar
effects on rod photoreceptors, which are the most abundant
subtype of photoreceptor cell. These cells are particularly
difficult to quantify in our paradigm due to their very large
numbers in the Xenopus tadpole retina. Xath5 is also thought to
be upstream of neuroD in photoreceptor specification (Ma et
al., 2004). In our experiments, increasing Pax6 levels resulted in
a decrease in Xath5 expression, a decrease in neuroD expression
and a decrease in photoreceptor numbers, consistent with this
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resulted in a decrease in Xath5, whereas neuroD expression and
photoreceptor numbers increased. These results indicate that
Xath5 is not necessary for cone photoreceptor production. In
order to elucidate the different pathways that may be down-
stream of pax6 for photoreceptor production, other factors need
to be tested.
pax6 effects on p27 expression also may affect cell type
specification. p27 drives cell cycle exit and premature
expression causes cells to differentiate into early born cell
types such as ganglion cells and photoreceptors (Ohnuma et al.,
1999). In our experiments, p27 expression was decreased when
Pax6 levels were increased at either stage and with pax6 loss-
of-function at stage 12. However, p27 expression was only
moderately affected transiently by pax6 loss-of-function at
stage 16. This correlates with the observed increase of ganglion
cells and cone photoreceptors, the earliest born cell types, after
stage 16 activation of dnPax6-GR. The persistence of p27
expression under this experimental condition may promote the
differentiation of these two cell types.
In summary, manipulating Rx1 and Pax6 levels/activity in
retinal stem and progenitors cells after the formation of the eye
field demonstrates that these two genes have differential effects
on the further differentiation of these cells. In general, increased
Rx1 levels appear to repress the production of cell types from
each retinal layer, whereas rx1 a loss-of-function expands
nearly all these cell types. Rx1 appears to cause these changes
by expanding a pool of primitive RSCs, thereby prolonging
proliferation, decreasing the expression of other retinal stem and
neural identity genes and repressing the expression of genes
involved in neuronal differentiation. In contrast, increased Pax6
levels promote ganglion cells and represses ONL and OINL
cells in a time-dependent manner, and decreasing Pax6 activity
promotes different cell types at different stages. pax6 appears to
define subsets of RSCs and RPCs that then form specific cell
types in the mature retina. Thus, while Rx1 and Pax6 are both
required for establishing the eye field, and are expressed in
similar domains in the various stem/progenitor pools (neural
plate, optic vesicle, optic cup, CMZ), their subsequent roles in
the specification of RSCs and RPCs are cooperative but distinct.
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